Short answer
Korro Bio, Inc. (KRRO) filed an 8-K current report with the SEC on March 9, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure). Private placement raising ~$85.0M gross proceeds via 4.5M shares at $11.11/share plus pre-funded warrants for 3.1M additional shares at $11.109 each.
Korro Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Private placement raising ~$85.0M gross proceeds via 4.5M shares at $11.11/share plus pre-funded warrants for 3.1M additional shares at $11.109 each
- Combined with existing $85.2M cash (as of Dec 31, 2025), total runway extended into 2H 2028: meaningful for a clinical-stage biotech burning cash on pipeline development
- High-profile syndicate led by Venrock Healthcare, with NEA, Balyasny, Nantahala, and Driehaus among participants: institutional validation of OPERA® RNA editing platform
- Pre-funded warrants carry 9.99% beneficial ownership blocker (adjustable to 19.99% with 61-day notice): standard dilution management tool
- Resale registration statement due within 30 days of closing; effectiveness deadline 60-90 days: liquidated damages triggered if deadlines missed, protecting investor liquidity
Item 2.02 · Results of Operations and Financial Condition
- Cash, cash equivalents & marketable securities ~$85.2M as of Dec 31, 2025 (preliminary, unaudited)
- Figure subject to change pending completion of financial closing procedures: not yet audited or reviewed by external auditors
- Runway visibility matters for clinical-stage biotech; $85.2M balance signals near-term funding status ahead of full earnings release
Item 3.02 · Unregistered Sales of Equity Securities
- Item 3.02 covers unregistered securities sales; KRRO's disclosure cross-references another section of this 8-K rather than detailing terms here
- Investors should review the full 8-K for deal terms, share counts, and applicable exemptions from registration
Item 7.01 · Regulation FD Disclosure
- Private placement closing disclosed: terms and size not specified in this section; check accompanying exhibits for deal economics
- Preliminary unaudited year-end cash, cash equivalents, and marketable securities referenced: actual figures not disclosed in this item
- Cash runway guidance flagged as forward-looking: subject to audit finalization risk before becoming confirmed figures
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Korro Bio, Inc. 8-K filings
Get the next KRRO 8-K as it lands
Follow KRRO for push alerts, or ask the research agent what this filing means.